Three years after Chris Hemsworth shared he had a gene that elevates his likelihood of developing Alzheimer’s, he detailed ...

Three years after Chris Hemsworth shared he had a gene that elevates his likelihood of developing Alzheimer’s, he detailed ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

The long-awaited Canadian approval of lecanemab has shifted physicians’ approach to Alzheimer’s disease, addressing previous ...

Millions of people are living with Alzheimer's disease, a progressive, irreversible brain disorder that causes cognitive decline, confusion, memory loss, and many other symptoms. The Alzheimer's Assoc ...

Emerging evidence suggests there may be a critical window for estrogen therapy to protect against cognitive decline later in ...

Data from the Evoke trials suggests that GLP-1 drugs that treat type 2 diabetes do not have a significant effect on Alzheimer ...

Scientists have identified a potential new treatment strategy for Alzheimer’s disease using a combination of two existing ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid ...